Scholar Rock in a hard place as biotech lays off 25% of staff, narrows pipeline and loses CMOnews2022-05-17T13:15:24+00:00May 17th, 2022|FierceBiotech|
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D centernews2022-05-17T11:34:14+00:00May 17th, 2022|FierceBiotech|
AstraZeneca bags pan-variant COVID-19 antibodies from stealthy biotech in $157M dealnews2022-05-17T10:06:04+00:00May 17th, 2022|FierceBiotech|
Remix closes $70M funding with pipeline ‘really humming,’ but to what tune?news2022-05-16T20:24:16+00:00May 16th, 2022|FierceBiotech|
After 14 years, Agios is looking for a partner to tango with, but tough changes lie aheadnews2022-05-16T19:49:08+00:00May 16th, 2022|FierceBiotech|
VC firm Sofinnova banks $1B from Apollo to invest in early-stage biotech solutionsnews2022-05-16T14:39:11+00:00May 16th, 2022|FierceBiotech|
AbbVie coughs up nearly $50M for Cugene’s autoimmune med in a bid to shore up life post-Humiranews2022-05-16T13:39:55+00:00May 16th, 2022|FierceBiotech|
To TIGIT or not to TIGIT? Roche’s latest trial flop casts shadow on Big Pharma’s $6B betnews2022-05-16T11:40:52+00:00May 16th, 2022|FierceBiotech|
From Redditors to creditors: Orphazyme’s wild ride ends with $13M sale to satisfy bankruptcy courtnews2022-05-16T10:07:21+00:00May 16th, 2022|FierceBiotech|
Shionogi splashes $100M on F2G’s rare fungal disease drug to unlock new class of medicinenews2022-05-16T09:30:07+00:00May 16th, 2022|FierceBiotech|
